| Literature DB >> 29301250 |
Yue Zhou1, Na Zhang2, Xiaoqian Qi3, Shan Tang4, Guohui Sun5, Lijiao Zhao6, Rugang Zhong7, Yongzhen Peng8.
Abstract
Protein kinase is a novel therapeutic target for human diseases. The off-target and side effects of ATP-competitive inhibitors preclude them from the clinically relevant drugs. The compounds targeting the druggable allosteric sites outside the highly conversed ATP binding pocket have been identified as promising alternatives to overcome current barriers of ATP-competitive inhibitors. By simultaneously interacting with the αD region (new allosteric site) and sub-ATP binding pocket, the attractive compound CAM4066 was named as allosteric inhibitor of CK2α. It has been demonstrated that the rigid linker and non-ionizable substituted fragment resulted in significant decreased inhibitory activities of compounds. The molecular dynamics simulations and energy analysis revealed that the appropriate coupling between the linker and pharmacophore fragments were essential for binding of CAM4066 with CK2α. The lower flexible linker of compound 21 lost the capability of coupling fragments A and B to αD region and positive area, respectively, whereas the methyl benzoate of fragment B induced the re-orientated Pre-CAM4066 with the inappropriate polar interactions. Most importantly, the match between the optimized linker and pharmacophore fragments is the challenging work of fragment-linking based drug design. These results provide rational clues to further structural modification and development of highly potent allosteric inhibitors of CK2.Entities:
Keywords: allosteric inhibitor; fragment-based design; linker; protein kinase CK2; αD region
Mesh:
Substances:
Year: 2018 PMID: 29301250 PMCID: PMC5796060 DOI: 10.3390/ijms19010111
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) The time dependence of RMSD of inhibitors (upper) and CK2α (lower) for CK2 in complex with CAM4066, Pre-CAM4066 and compound 21; and (B) calculated per-residue B-factor of three complexes systems.
Figure 2(A) Superimposition of co-crystallized pose (gray stick) and the average structure (white stick) of CAM4066; and (B) interactions between CAM4066 and the residues in the active site.
Figure 3(A) Superimposition of co-crystallized pose (gray stick) and the average structure (white stick) ofcompound 21; (B) stable binding mode of compound 21 with the residues in the active site; (C) superimposition of co-crystallized pose (gray stick) and the average structure (white stick) of compound Pre-CAM4066; and (D) stable binding mode of compound Pre-CAM4066 with the residues in the active site.
Figure 4The dihedral N1-C8-C9-C10 and C8-C9-C10-N2 as the time evolution of CAM4066 and compound 21.
Energy terms of MM/PBSA results for three CK2α-inhibitor complexes systems.
| Energy Term (kcal/mol) | CAM4066 | Compound 21 | Pre-CAM4066 |
|---|---|---|---|
| Δ | −110.41 ± 2.83 | −53.42 ± 3.87 | −11.17 ± 4.26 |
| Δ | −75.00 ± 3.16 | −65.18 ± 3.64 | −68.35 ± 4.09 |
| Δ | −185.41 ± 5.23 | −118.60 ± 3.64 | −79.52 ± 4.52 |
| Δ | −8.56 ± 0.13 | −8.29 ± 0.19 | −8.89 ± 0.18 |
| Δ | 139.29 ± 4.18 | 75.46 ± 4.42 | 40.24 ± 2.94 |
| Δ | 130.72 ± 3.15 | 67.16 ± 3.36 | 31.35 ± 2.96 |
| Δ | 28.88 ± 5.32 | 22.04 ± 3.15 | 29.07 ± 3.98 |
| Δ | −54.68 ± 4.87 | −51.43 ± 4.42 | −48.17 ± 3.33 |
| ΔΔ | 0 | 3.25 | 6.51 |
a ΔEgas = ΔEele + ΔEvdw; b ΔGsol = ΔGpolar + ΔGnonpolar; c ΔGele = ΔEele + ΔGpolar; d ΔGbinding = ΔEele + ΔEvdw + ΔGsol.
Chemical structures, K and IC50 values of CAM4066, Pre-CAM4066 and compound 21.
| Compound | Fragment A | Linker | Fragment B | IC50 (μM) | PDB | |
|---|---|---|---|---|---|---|
| CAM4066 | 0.370 | 0.320 | 5CU4 | |||
| Pre-CAM4066 | n/a | n/a | n/d | |||
| 21 | n/a | 1.64 | 5MO8 |
n/a = not active; n/d = not determined.